Assessing Acadia Pharmaceuticals (ACAD) Valuation After Strong Q3 Results and Extended NUPLAZID Patent Protection [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
Acadia Pharmaceuticals (ACAD) is back in focus after a stronger than expected third quarter pushed analysts to lift their sales estimates, helped by NUPLAZID's patent protection, which now runs through 2030.
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett SyndromeBusiness Wire
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Stifel Nicolaus from $24.00 to $25.00. They now have a "hold" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (ACAD) Is Up 9.6% After Earnings Beat And NUPLAZID Patent Extension News [Yahoo! Finance]Yahoo! Finance
- Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]Seeking Alpha
ACAD
Earnings
- 11/5/25 - Beat
ACAD
Sec Filings
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- 11/14/25 - Form SCHEDULE
- ACAD's page on the SEC website